<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2437">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01545765</url>
  </required_header>
  <id_info>
    <org_study_id>RD.03.SPR29103</org_study_id>
    <nct_id>NCT01545765</nct_id>
  </id_info>
  <brief_title>Anesthetic Effect Duration Assessment</brief_title>
  <official_title>Anesthetic Effect Duration Produced by Lidocaine 7% + Tetracaine 7% Cream on 2 Different Body Areas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the duration of anesthetic effect produced ,
      Lidocaine7% + Tetracaine 7% cream when applied with 2 different application times on the
      face and thigh.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will have 4 target zones defined; 2 on the face and 2 on the anterior thighs. Upon
      inclusion into the study, subjects will have the study drug applied with a different
      application time to one side of the face and anterior thigh according to the randomization.
      After the completion of the application process, study drug on both sides of the face and on
      both anterior thighs will be removed by peeling.

      After drug removal, the duration of anesthetic effect of the study drug will be tested using
      a pinprick test. Five (5) pinpricks using a 21-gauge needle will be performed at the 4
      target zones (each side of the face and both anterior thighs). The pinprick test will be
      repeated up to 8 hours after drug removal. There will be a total of 20 post drug removal
      pinprick test completed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Duration of Anesthesia(Minutes)</measure>
    <time_frame>From T0 (product removal) up to T8 hours after product removal</time_frame>
    <safety_issue>No</safety_issue>
    <description>Onset and end of anesthesia are evaluated by Pinprick tests. Duration of anesthesia is calculated as: difference between onset and end of anesthesia (minutes).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>During the study</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of adverse events was to be reported during the study period</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>lidocaine 7% and tetracaine 7%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine 7% + Tetracaine 7% cream</intervention_name>
    <description>Study drug will be applied with a different application time to one side of the face and anterior thigh according to the randomization list.</description>
    <arm_group_label>lidocaine 7% and tetracaine 7%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male of female subjects aged 18 or older with a normal not excessive hairy
             skin,

        Exclusion Criteria:

          -  Female subjects who are pregnant or breast-feeding; or plan to become pregnant,

          -  Subjects who have a known allergy to one of the components of the test drug
             lidocaine, tetracaine or other local anesthetics,

          -  Subjects who are at risk in terms of precautions, warnings, and contra-indication
             with the study product.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Regina YAVEL, MD- Dermatologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Galderma investigational center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Galderma Investigational center</name>
      <address>
        <city>Rochelle Park</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 25, 2013</lastchanged_date>
  <firstreceived_date>February 24, 2012</firstreceived_date>
  <firstreceived_results_date>June 25, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Tetracaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>31 healthy volunteers have been enrolled in one Phase I center at USA.First subject in: May 3d 2012; Last subject ou: May 26th 2012.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Face 2 Application Times/ Thight 2 Application Times</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>No sample size determination as a standard sample size for this type of study is about 30 subjects.</population>
      <group_list>
        <group group_id="B1">
          <title>Lidocaine 7% and Tetracaine 7%</title>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="31"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="47.2" spread="1.27"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="31"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Incidence of adverse events was to be reported during the study period</description>
        <time_frame>During the study</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>A standard sample size for this type of study is 30 subjects. The analyses are performed on the safety population (APT), corresponding to the enrolled and randomized population, after exclusion of subjects who never applied the treatments with certainty. Missing data were to be treated as missing for all analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine 7% + Tetracaine 7% Face - First Application Time</title>
          </group>
          <group group_id="O2">
            <title>Lidocaine 7% + Tetracaine 7% Face - Second Application Time</title>
          </group>
          <group group_id="O3">
            <title>Lidocaine 7% + Tetracaine 7% Thigh - First Application Time</title>
          </group>
          <group group_id="O4">
            <title>Lidocaine 7% + Tetracaine 7% Thigh - Second Application Time</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                  <measurement group_id="O2" value="31"/>
                  <measurement group_id="O3" value="31"/>
                  <measurement group_id="O4" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Adverse Events</title>
            <description>Incidence of adverse events was to be reported during the study period</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of Anesthesia(Minutes)</title>
        <description>Onset and end of anesthesia are evaluated by Pinprick tests. Duration of anesthesia is calculated as: difference between onset and end of anesthesia (minutes).</description>
        <time_frame>From T0 (product removal) up to T8 hours after product removal</time_frame>
        <safety_issue>No</safety_issue>
        <population>A standard sample size for this type of study is 30 subjects. The analyses are performed on the safety population (APT), corresponding to the enrolled and randomized population, after exclusion of subjects who never applied the treatments with certainty. Missing data were to be treated as missing for all analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine 7% + Tetracaine 7% Face - First Application Time</title>
          </group>
          <group group_id="O2">
            <title>Lidocaine 7% + Tetracaine 7% Face - Second Application Time</title>
          </group>
          <group group_id="O3">
            <title>Lidocaine 7% + Tetracaine 7% Thigh - First Application Time</title>
          </group>
          <group group_id="O4">
            <title>Lidocaine 7% + Tetracaine 7% Thigh - Second Application Time</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                  <measurement group_id="O2" value="31"/>
                  <measurement group_id="O3" value="31"/>
                  <measurement group_id="O4" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Duration of Anesthesia(Minutes)</title>
            <description>Onset and end of anesthesia are evaluated by Pinprick tests. Duration of anesthesia is calculated as: difference between onset and end of anesthesia (minutes).</description>
            <units>Minutes</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="80" lower_limit="0" upper_limit="420"/>
                  <measurement group_id="O2" value="140" lower_limit="0" upper_limit="480"/>
                  <measurement group_id="O3" value="0" lower_limit="0" upper_limit="460"/>
                  <measurement group_id="O4" value="400" lower_limit="0" upper_limit="480"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All study period (from Baseline to end of teh study)</time_frame>
      <desc>Incidence of adverse events was to be reported during the study</desc>
      <group_list>
        <group group_id="E1">
          <title>Lidocaine 7% + Tetracaine 7%</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>SINUS HEADACHE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any intent of the investigator to publish or disclose in any way the information requires the sponsor's prior written approval. The investigator shall provide their draft of such publication to sponsor to review and approval at least 2 months prior to the date of intended publication. Sponsor shall have the absolute right to determine whether information may be published by the investigator.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No limitation or caveat on this study</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Farzaneh Sidou Clinical Project Manager)</name_or_title>
      <organization>Galderma</organization>
      <phone>00.33.4.93.95.70.70</phone>
      <email>farzaneh.sidou@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
